<DOC>
	<DOCNO>NCT02506842</DOCNO>
	<brief_summary>The purpose study investigate activity safety second-line adjuvant therapy nab-paclitaxel plus gemcitabine ( AG ) versus oxaliplatin plus folinic acid fluorouracil ( OFF ) gemcitabine-refractory pancreatic cancer curative resection .</brief_summary>
	<brief_title>Second-Line Adjuvant Therapy With Nab-Paclitaxel Plus Gemcitabine Versus Oxaliplatin Plus Folinic Acid Fluorouracil Gemcitabine-Refractory Pancreatic Cancer After Curative Resection</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : - To evaluate therapeutic efficacy second-line adjuvant therapy nab-paclitaxel plus gemcitabine ( AG ) versus oxaliplatin plus folinic acid fluorouracil ( OFF ) term overall survival gemcitabine-refractory pancreatic cancer curative resection . SECONDARY OBJECTIVES : - To evaluate therapeutic efficacy two regimen term objective response rate accord Response Evaluation Criteria Solid Tumors ( RECIST ) version 1.1 - To evaluate time remission patient treat two regimen . - To evaluate progression-free survival patient treat two regimen . - To evaluate level tumor biomarkers serum patient treat two regimen , include Carbohydrate Antigen ( CA ) 19-9、CA125、CA153、CA242、CA72-4、CA50、CEA、AFP . - To evaluate occurrence grade 3 4 toxicity accord National Cancer Institute Common Toxicity Criteria Adverse Effects ( NCI CTCAE ) version 4.0 patient treat two regimen . - To evaluate quality life score patient treat two regimen . Detailed Description Arms : Patients randomize 1 2 treatment arm ( Arm AG Arm OFF ) . Arm AG : Firstly , patient receive nab-paclitaxel 100 mg/m^2 ( iv , 30 minute ) day 1 , 8 , 15 3 week , follow one week without treatment . Secondly , patient receive gemcitabine 1000 mg/m^2 ( iv , 30 minute ) day 1 , 8 , 15 3 week , follow one week without treatment . Treatment repeat disease progression recurrence . Arm OFF : Patients receive oxaliplatin 85 mg/m^2 ( iv , 2 hour ) day 8 22 42 day cycle . Patients receive folinic acid 200 mg/m^2 ( iv ) fluorouracil 2000 mg/m^2 ( iv , 24 hour ) day 1 , 8 , 15 22 4 week , follow 2 week without treatment . Oxaliplatin give folinic acid fluorouracil three drug give day . Treatment repeat disease progression recurrence .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>Signed informed content obtain prior treatment Age ≥ 18 year ≤ 75 year Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Patients must histologically confirm pancreatic adenocarcinoma ( mixed pathology adenocarcinoma predominant ) R0 R1 resection . The pathological staging exceed stage ⅡB . And patient receive gemcitabine adjuvant chemotherapy curative resection . There progression recurrence tumor course adjuvant chemotherapy gemcitabine , within 6 month whole course treatment . No severe defect hematological system , immune system , cardiac function pulmonary function . White blood cell ( WBC ) ≥ 4 × 10^9/L ; Absolute neutrophil count ( ANC ) ≥ 1.5 × 10^9/L ; Platelets ( PLT ) ≥ 100 × 10^9/L ; Hemoglobin ( Hgb ) ≥ 9 g/dL Aspartate aminotransferase ( AST ) ( serum glutamate oxaloacetate transaminase ( SGOT ) ）/ alanine aminotransferase ( ALT ) ( serum glutamate pyruvate transaminase ( SGPT ) ) ≤ 2.5 × institutional upper limit normal ( ULN ) ; Total bilirubin ( TBIL ) ≤ ULN ; Creatinine ( CRE ) ≤ 1.5 × ULN Prothrombin time ( PT ) international normalize ratio ( INR ) ≤ 1.5 × ULN The patient willing comply study plan requirement . There another malignant tumor patient . Patients receive form antitumor therapy within 4 week prior enrollment , include chemotherapy , radiotherapy , interventional chemoembolization , radiofrequency ablation , molecular target therapy Use investigational agent within 4 week prior enrollment . The progression recurrence tumor occur 6 month course adjuvant chemotherapy gemcitabine . Patients uncontrolled intercurrent illness include , limited ongoing active infection , internal hemorrhage , pancreatic leakage , bile leakage , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . History allergic reaction attribute compound similar chemical biological composition drug . Metabolic acidosis , acute chronic , include ketoacidosis Pregnant nursing woman Any event condition possible harm safety patient integrity data , include severe medical risk factor , medical condition , laboratory disorder . Patients unwilling unable comply study procedure , may absent observation 7 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Pancreatic Cancer</keyword>
	<keyword>Pancreatic Adenocarcinoma</keyword>
	<keyword>AG</keyword>
	<keyword>OFF</keyword>
	<keyword>Second-Line Adjuvant Therapy</keyword>
</DOC>